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Internal tandem duplication of FLT3 (FLT3-ITD) is one of the most common somatic
mutations in acute myeloid leukemia (AML); it causes constitutive activation of FLT3 kinase
and is associated with high relapse rates and poor survival. Small-molecule inhibition of
FLT3 represents an attractive therapeutic strategy for this subtype of AML, although
resistance from secondary FLT3 tyrosine kinase domain (FLT3-TKD) mutations is an
emerging clinical problem. CCT241736 is an orally bioavailable, selective, and potent dual
inhibitor of FLT3 and Aurora kinases. FLT3-ITD1 cells with secondary FLT3-TKD mutations
have high in vitro relative resistance to the FLT3 inhibitors quizartinib and sorafenib, but
not to CCT241736. The mechanism of action of CCT241736 results in significant in vivo
efficacy, with inhibition of tumor growth observed in efficacy studies in FLT3-ITD and FLT3-
ITD-TKD human tumor xenograft models. The efficacy of CCT241736 was also confirmed in
primary samples from AML patients, including those with quizartinib-resistant disease,
which induces apoptosis through inhibition of both FLT3 and Aurora kinases. The unique
combination of CCT241736 properties based on robust potency, dual selectivity, and
significant in vivo activity indicate that CCT241736 is a bona fide clinical drug candidate for
FLT3-ITD and TKD AML patients with resistance to current drugs.
Introduction
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is associated with poor
outcomes for many patients.1 FLT3 is a class 3 receptor tyrosine kinase, a class that includes platelet-
derived growth factor receptor a and b, c-KIT, and c-fms.2 It is expressed in a variety of human and
murine cell lines of both myeloid and B-lymphoid lineage. When activated by its cognate FLT3 ligand
(FL), it initiates downstream signaling via the phosphatidylinositol 3-kinase/AKT/mTOR pathway. FLT3
also activates the Ras/Raf/MEK/ERK pathway via Src homology and collagen (SHC) proteins and
GRB2-binding protein (GAB2), which leads to downstream activation of cyclic adenosine mono-
phosphate response element-binding protein (CREB) and signal transducer and activator of
transcription 5 (STAT5).3,4 Mutation of the FLT3 gene is a frequent event in AML and usually involves
internal tandem duplication (ITD) of the juxtamembrane domain coding region or point mutations of the
tyrosine kinase domain (TKD).5 Both FLT3-ITD and FLT3-TKD mutations result in ligand-independent
proliferation because of the constitutive dimerization and activation of the FLT3 receptor.5
Several small molecule kinase inhibitors targeting FLT3 have been evaluated in AML patients, but the
clinical impact has thus far been limited because of the transient responses when they are used as single
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agents and the emergence of acquired resistance after treatment.6
One particular mechanism of resistance is acquired secondary
mutations in FLT3-TKD. All 9 patients analyzed from the phase 2
study of AC220 (quizartinib) who relapsed after achieving complete
bone marrow responses had secondary FLT3-TKD mutations (at
residues F691 or D835) on the FLT3-ITD1 allele.7 Similarly,
secondary FLT3-TKD mutations at D835 have been identified in
FLT3-ITD patients relapsing after initially successful therapy with
sorafenib. Importantly, evidence suggests that double FLT3-ITD-
TKD mutations are present in treatment-naı¨ve, leukemia-initiating
subclones and are selected out by therapy with sorafenib.8 In
addition to secondary FLT3-TKD mutations, increased levels of FL
have also been demonstrated to cause relative resistance to FLT3
inhibitors.9
Aurora kinases are a family of highly conserved serine-threonine
protein kinases that play a key role in several stages of mitosis.10 An
increase in the expression of Aurora A is associated with poor
prognosis in a range of cancers, including leukemia in which
overexpression of Aurora A has been consistently demonstrated.11
Aurora A inhibition by alisertib has been shown to arrest cells in the
G2-M phase in a dose- and time-dependent manner.
12 AML
patients express a disproportionate number of undifferentiated
cells (CD341/CD38–), which aberrantly express greater levels of
Aurora A than their CD341/CD381 counterparts. This undifferen-
tiated population shows greater sensitivity to alisertib.13 Alisertib
has been demonstrated to have modest single-agent activity in
a phase 2 clinical trial (NCT00830518) in AML patients. Although
17% of patients showed a complete or partial response and 49%
showed stable disease, there was no causal link between disease
subtype and progression and response rate.14
Here, we report the preclinical activity of CCT241736, a potent,
orally bioavailable, dual FLT3-Aurora kinase inhibitor.15 In both
in vitro and in vivo models, we demonstrated that the presence of
secondary TKD mutations (D835Y and F691L) in a human FLT3-
ITD1 AML cell line or exposure to increased levels of FL result in
high relative resistance to the FLT3 inhibitor AC220 but not to
CCT241736. In addition, CCT241736 induces apoptosis in primary
samples from patients with AML and those with quizartinib-resistant




The human AML cell lines MOLM-13 and MV4-11 were purchased
from the German Collection of Microorganisms and Cell Cultures
(DSMZ). The DSMZ authenticates all human cell lines by DNA
typing and confirms species of origin by polymerase chain reaction
analysis. Working stocks for the experiments described in this study
were prepared immediately upon receipt of cells from DSMZ. Both
cell lines are FLT3-ITD116 and were maintained in antibiotic-free
RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (FBS; PAA Laboratories Ltd, Somerset,
United Kingdom). MOLM-13 cells with resistance to the FLT3
inhibitor MLN518 (tandutinib; hereafter MOLM-13-RES) were
developed by culturing MOLM-13 cells in the presence of
increasing concentrations of MLN518 (with#0.1% dimethyl sulfoxide
[DMSO]) until confluent growth was sustained in 5 mM MLN518 as
described previously.17 Experiments using MOLM-13-RES cells were
carried out after at least overnight incubation in MLN518-free RPMI
1640 medium with 10% FBS. The same method was used to
generate the MOLM-13-RES-AC cell line by using increasing
concentrations of AC220 up to approximately 1 mM.
Compounds
CCT241736 and CCT137690 were discovered and synthesized
at our Institute,15,18 and MLN518 and sorafenib were purchased
from LC Laboratories (Woburn, MA). AC220 was purchased
from Activate Scientific GmbH (Prien, Germany). Nocodazole and
cytarabine were purchased from Sigma-Aldrich (St. Louis, MO). All
compounds were dissolved in DMSO and stored at 220°C.
In vitro kinase assays
The concentration of the compound that inhibited FLT3 and FLT3
(D835Y) kinase activity by 50% of normal (IC50) was determined
by Z9-LYTE assay using Invitrogen’s SelectScreen Biochemical
Kinase Profiling Service (Invitrogen, Paisley, United Kingdom). The
adenosine triphosphate concentration used for these assays was
equal to Km apparent.
Cellular assays
To assess cell viability in vitro, all cell lines were seeded into 96-well
plates at a density of 2 3 105 cells per 100 mL and then treated
with 0.2% DMSO or varying concentrations of CCT241736,
CCT137690, or MLN518 for 72 hours. Cell viability was measured
using the CellTiter 96 AQueous One Solution Cell Prolifera-
tion Assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium [MTS]; Promega, Madison,WI) with
absorbance measured at 490 nm using a Wallac Victor2 1420
multilabel counter (PerkinElmer Life Sciences, Cambridgeshire,
United Kingdom). For cellular assays to assess inhibition of kinase
signaling pathways and apoptosis, cell lines were seeded at varying
concentrations in 12- or 24-well plates or 25 cm2 flasks, respectively.
Immunoblotting
Protein extraction was performed as previously described,17 and
the extracted proteins were immunoblotted with the following
antibodies: phospho-Aurora-A (Thr288)/Aurora-B (Thr232)/Aurora-
C (Thr198), Aurora-A, phospho-FLT3 (Tyr 842), phospho-STAT5
(Tyr694), STAT5, phospho-p44/42 MAPK (Thr202/Tyr204), p44/
42 MAPK, and poly (ADP-ribose) polymerase (PARP) (all from Cell
Signaling Technology, Danvers, MA); FLT3 (C-20, Santa Cruz
Biotechnology, Santa Cruz, CA); Aurora-B and histone H3 (HH3)
(both from Abcam); and phospho-histone H3 (Ser10) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (both from
Millipore, Billerica, MA). For detection of phosphorylated FLT3 in
xenograft samples, cell lysates were immunoprecipitated with FLT3
antibody and protein A sepharose (GE Healthcare, Buckingham-
shire, United Kingdom), resolved by electrophoresis, immunoblotted
onto polyvinylidene fluoride membranes (Millipore, Billerica, MA),
and probed with a phospho-tyrosine (4G10) antibody (Millipore).
After exposure, membranes were stripped with 5% acetic acid and
then re-probed with the total FLT3 antibody. All membranes were
incubated with secondary anti-rabbit or anti-mouse antibodies
conjugated to horseradish peroxidase (Dako, Glostrup, Denmark),
developed by using enhanced chemiluminescence substrate (Thermo
Fisher Scientific, Rockford, IL) and exposed on enhanced chemilumi-
nescence Amersham Hyperfilm (GE Healthcare). Apoptosis was
examined by detection of PARP cleavage using immunoblotting.
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Cell cycle analysis
Cells were fixed overnight at 4°C in 70% ethanol, washed in
phosphate-buffered saline (PBS) (with 1% FBS), and then
incubated for 30 minutes in PBS with 1% FBS, 0.04% propidium
iodide, and 0.25% RNase. Cells were analyzed using a BD LSRII
flow cytometer (BD Biosciences).
Patient samples
Peripheral blood samples were obtained from newly diagnosed
AML and quizartinib-resistant AML patients at Royal Marsden
Hospital. After written informed consent was provided, the study
was approved by the East of England-Cambridge South Research
Ethics Committee. All studies complied with the rules of the Review
Board and the revised Helsinki protocol. The samples were
collected at untreated presentation or relapse, and mononuclear
cells were obtained by density gradient centrifugation. Patients with
available cytogenetic data were classified according to the Medical
Research Council classification system.19
Primary cell assays
Mouse stromal cell line MS-5 obtained from DSMZ (Braunschweig,
Germany) was used to support human AML primary cells. MS-5
cells were irradiated with 7.5 Gy using a gamma irradiator and
cultured in Minimal Essential Medium alpha supplemented with
10% heat-inactivated FBS and penicillin-streptomycin in 12-well
plates at a density of 5 3 104 cells per milliliter in a humidified
incubator containing 5% CO2 at 37°C. After 24 hours, AML cells
were cocultured in triplicate onto irradiated MS-5 cells at a density
of 1.2 million cells per milliliter with 3 different doses of FLT3
inhibitor. Three days after treatment, cells were harvested and
counted using a Luna-II Automated Cell Counter (Labtech). Annexin
V and Vybrant FAM caspase-3 and caspase-7 (caspase-3/-7)
assays were also used to assess apoptosis.
Apoptotic assays
For annexin V assays, cells were washed using annexin V binding
buffer (BD Biosciences), suspended at a concentration of 1 3 106
cells per milliliter, and incubated with annexin V-fluorescein
isothiocyanate and human CD45-allophycocyanin simultaneously
for 15 minutes at room temperature in the dark. Cells were then
washed and resuspended in PBS with 2% fetal calf serum and 49,6-
diamidino-2-phenylindole (DAPI) and analyzed on a BD FACS-
Canto II cytometer. Annexin V–positive cells (both DAPI negative
and DAPI positive) were defined as apoptotic cells. Caspase-3/-7
activity was measured using the Vybrant FAM caspase-3/-7 assay
according to the manufacturer’s instructions (Invitrogen). Cells
were analyzed on a BD FACSCanto II cytometer and analyzed with
FlowJo software.
Animal efficacy studies
All animal studies were approved by the local research ethics
committee and were carried out in accordance with the United
Kingdom Animals (Scientific Procedures) Act 1986 and national
guidelines.20 Athymic CrTac:NCr-Fox1 (nu) mice were bred in-
house. Female mice 6 to 8 weeks old were injected subcutaneously
in the right flank with 2 3 106 MOLM-13 or MOLM-13-RES cells.
When mean tumor diameter was 6 mm (at ;day 5), mice were
assigned to treatment or control cohorts (8 mice each), and dosing
began with the vehicle, CCT241736, MLN518, or AC220 at
the indicated doses. Tumors were routinely measured across 2
perpendicular diameters, and volumes were calculated by using the
formula V 5 4/3p [(d1 1 d2)/4].3 Cohorts of mice were culled at
specified times after the final dose, and tumors were excised,
weighed, measured, and processed for pharmacokinetic (PK) and
pharmacodynamic (PD) analyses. For the systemic model, 2 3 105
BaF3FLT3-ITD F691L luciferase-expressing cells were injected into
NOD SCID mice. Mice were dosed with vehicle control 4 days after
tumor cell implantation and randomization. Half the mice received
a combination of DMSO (10%), Tween 80 (5%), PEG 400 (20%),
and water (65%) and half received hydroxypropyl b cyclodextrin
(22%), AC220 5 mg/kg orally once per day, and CCT241736
100 mg/kg orally twice per day; tumor burden was then assessed
by whole-body bioluminescent imaging. Animals were culled when
they showed signs of deterioration due to tumor burden (body
weight loss, rapid breathing).
Statistics
All statistical analyses were performed using GraphPad Prism 5
software (GraphPad Software Inc, La Jolla, CA). In vitro log dose-
response curves were calculated using nonlinear regression with
variable slope after normalizing absorbance to untreated and cellular
controls with the concentration required to inhibit the MTS response
by 50% reported as the viability IC50. For in vivo studies, survival was
calculated using the Kaplan-Meier method.
Results
In vitro activity, efficacy, and mechanism of action of
CCT241736 in AML cell lines
We have shown that CCT241736 is a potent dual inhibitor of FLT3
and Aurora kinases with few off-target kinase activities across the
human kinome.15 In addition, CCT241736 did not inhibit the major
cytochrome P450 isoforms and hERG, with IC50 values greater
than 10 mM. The PK profile of CCT241736 in mice and rats
revealed a compound with high oral bioavailability, low clearance,
and a moderate volume of distribution.15
To assess the cell-based activity of CCT241736 alongside the
selective FLT3 inhibitor MLN518, we used FLT3-ITD1 MOLM-13
and MV4-11 AML cell lines together with KG-1a AML cell lines that
were FLT3 wild-type (WT) (representative graphs in supplemental
Figure 1A-C). In a 72-hour MTS proliferation assay, both CCT241736
and MLN518 potently inhibited the viability of both MOLM-13 (growth
inhibition [GI50], 0.1 mM and 0.034 mM, respectively) and MV4-11
(GI50, 0.29 mM and 0.11 mM, respectively). CCT241736 but
not MLN518 inhibited the viability of the KG-1a FLT3 WT cell line
(GI50, 1 mM and .20 mM, respectively).
To confirm that the loss of cell viability in FLT3-ITD1 cells treated
with dual FLT3-Aurora inhibitor was associated with apoptosis,
MOLM-13 cells were treated with CCT241736 and analyzed for 2
different markers of apoptosis. Immunoblotting of cell lysates
confirmed PARP cleavage as well as downregulation of survivin in
a concentration-dependent manner at both 24 and 48 hours after
treatment (Figure 1A). At a 0.5 mM concentration of CCT241736,
there was robust cleavage of PARP at both time points and
a complete loss of survivin expression, thus confirming that the loss
of cell viability after treatment with CCT241736 was the result of
induction of apoptosis.
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Inhibition of Aurora A kinase classically results in temporary G2-M
arrest and cytokinesis failure followed by cell death, whereas Aurora
B inhibition causes polyploidy due to abrogation of the mitotic
checkpoint, failure of cytokinesis, and endoreduplication followed
by cell death at longer treatments (.48 hours).21 FLT3 inhibition
with compounds such as CEP-701 and FI-700 has been shown to
cause G1 arrest, with a decrease in the S and G2-M populations. To
determine whether the cell cycle effects of dual FLT3-Aurora
inhibition were different from selective inhibition of either kinase
alone, MOLM-13 cells were treated for 72 hours with CCT241736
(dual FLT3-Aurora), MLN518 (FLT3 selective), PHA-739358
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Figure 1. Induction of apoptosis, cell cycle regulation, and in vitro inhibition of FLT3 and Aurora signaling by CCT241736 in MOLM-13 cells. (A) Immunoblotting
analysis of cells treated with CCT241736 at the indicated concentrations for 24 and 48 hours using antibodies specific for cleaved PARP and survivin. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a loading control. (B) Cell cycle profile of MOLM-13 cells treated with FLT3 and Aurora kinase inhibitors or their
combinations: CCT241736, MLN518, PHA-739358, or MLN518 1 PHA-739358. MOLM-13 cells were treated for 72 hours with the compounds at the indicated
concentrations approximating their viability IC50 and 10 3 IC50, and they were fixed, stained, and analyzed by fluorescence-activated cell sorting (FACS). Y-axes represent
FACS event counts (same scale for all histograms). The percentage of cells in sub-G1, G1, S, G2, and 8N phases of the cell cycle are included. (C) After overnight incubation
with 50 ng/mL nocodazole, MOLM-13 cells were treated with CCT241736, CCT137690, or MLN518 for 2.5 hours at the indicated concentrations. Cell lysates were prepared
and analyzed for the expression of the indicated proteins by immunoblotting using specific antibodies. GAPDH was used as loading control.
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and PHA-739358 (Figure 1B). Upon treatment with IC50 concen-
trations, there were no striking effects on the cell cycle profile for
CCT241736 (0.1 mM) or MLN518 (0.035 mM). PHA-739358
caused polyploidy, with a small population of cells having 8N DNA
content (0.05 mM). At concentrations 10-fold higher, MLN518
produced G1-S arrest, and CCT241736 caused both G1-S and
G2-M arrest, whereas PHA-739358 caused increased polyploidy
with a larger population of cells having 8N DNA content. It was
notable that CCT241736 did not cause polyploidy. The phenotype
of G1-S– and G2-M–arrested cells seen with CCT241736, distinct
from the profile of the selective FLT3 inhibitor MLN518, was also
seen in cells treated with a combination of MLN518 and PHA-
739358, suggesting that in the setting of combined FLT3 and
Aurora inhibition, polyploidy is abrogated. This particular profile
mimics inhibition of both Aurora A and FLT3, consistent with the
kinase profile of CCT241736 in biochemical assays. These data
show the differences in mechanism of action between CCT241736
and the FLT3 selective (MLN518) or pan-Aurora (PHA-739358)
inhibitors.
To assess biomarker modulation upon treatment with CCT241736,
MOLM-13 cells were exposed to increasing concentrations of
CCT241736, CCT137690 (an alternative FLT3-Aurora tool in-
hibitor compound with a slightly different selectivity profile of Aurora
kinases compared with CCT241736),17,18 or MLN518. To more
clearly assess the inhibition of endogenous Aurora A and B kinases,
cells were incubated with nocodazole 50 ng/mL overnight to induce
mitotic arrest, thus increasing the percentage of cells with high
Aurora kinase expression. Immunoblotting was then performed on
cell lysates to examine the inhibition of FLT3 (P-FLT3, P-STAT5,
P-44/42-MAPK), and Aurora kinase signaling (P-Aurora A, P-Aurora
B, P-HH3). In some cell lines, CCT137690 showed higher potency
compared with CCT241736; however, the narrow safety margin
against hERG of CCT137690 limited its further progression.18
Inhibition of FLT3 and downstream signaling was observed with all
3 compounds, whereas inhibition of Aurora kinase and downstream
signaling was observed only with the 2 FLT3-Aurora inhibitors
(Figure 1C; supplemental Figure 2).
Resistance to selective FLT3 inhibition
In view of the potency seen in vitro in MOLM-13 cells and the ability
of CCT241736 to inhibit various FLT3-TKD mutations, it was
hypothesized that dual FLT3-Aurora inhibitor CCT241736 may
overcome resistance to selective FLT3 inhibitors such as MLN518
and AC220. Two important mechanisms of FLT3 inhibitor re-
sistance were assessed: secondary FLT3-TKD mutations and
increased FL levels. We have previously reported the generation
of an AML cell line resistant to selective FLT3 inhibition through
continuous culture of MOLM-13 cells in the presence of pro-
gressively increasing concentrations of MLN518.17 The resultant
MOLM-13-RES cells had a new point mutation at D835, in addition
to the original FLT3-ITD. As with other cell lines, the in vitro
sensitivity of MOLM-13-RES cells to CCT241736 and MLN518
was assessed by MTS assay. CCT241736 potently inhibits WT and
mutated FLT3 as well as the growth of MOLM-13 and MOLM-13-
RES cells compared with MLN518: GI50 of CCT241736, 0.1 mM in
MOLM-13 and 0.18 mM in MOLM-13-RES vs GI50 of MLN518,
0.03 mM in MOLM-13 and 3.57 mM in MOLM-13-RES. The
biochemical activities of CCT241736 (Kd) were FLT3-WT,
0.006 mM; FLT3-ITD, 0.038 mM; and FLT3-D835Y, 0.014 mM.






























































































































































































































































 user on 26 M
ay 2020
FLT3-ITD, 0.009 mM; and FLT3-D835Y, 1.8 mM. Although MLN518
potently inhibits wild-type and FLT3-ITD, it displays reduced activity
in FLT3-D835Y and MOLM-13-RES cells (representative graphs in
supplemental Figure 1D-E).
The inhibition of biomarkers downstream of FLT3 and Aurora kinase
was examined in the FLT3 inhibitor–resistant cell line MOLM-13-
RES in vitro. MOLM-13-RES cells were exposed to CCT241736 or
CCT137690 or AMG-900 (a pan-Aurora inhibitor) for 4 hours at the
indicated concentrations. Cells were then harvested and the levels
of the downstream markers of FLT3 (P-STAT5) and Aurora kinase
(phospho-histone H3 [P-HH3]) were evaluated. Levels of total
STAT5 and total HH3 were used as controls. As expected,
CCT241736 showed both FLT3 and Aurora kinase inhibition,
MLN518 showed complete FLT3 inhibition only at high concen-
trations (5 mM) compared with CCT241736 and CCT137690
(0.5 mM), and AMG-900 showed Aurora inhibition with low
FLT3 inhibition at high concentrations (Figure 2A). Although
CCT137690 showed robust FLT3 pathway inhibition, it showed
a weak P-HH3 inhibition. To more clearly assess the inhibition of
endogenous Aurora A and B kinases, MOLM-13-RES cells were
incubated with nocodazole to induce mitotic arrest. Immuno-
blotting was then performed on cell lysates to examine the
inhibition of FLT3 pathway (P-STAT5) and Aurora kinases
(P-Aurora A, P-Aurora B, P-HH3) by CCT137690 compared
with MLN518. CCT137690 clearly inhibits both FLT3 pathway
(P-STAT5) and Aurora kinases (P-Aurora A, P-Aurora B, and
P-HH3), whereas MLN518 inhibits only the FLT3 pathway
(supplemental Figure 2).
To examine the potency of CCT241736 in other clinically relevant
secondary FLT3-TKD mutations, we used a panel of BaF3 cells
expressing FLT3-ITD or a range of clinically relevant FLT3-TKD
mutants (Table 1; supplemental Figure 1F). Mutant FLT3-ITD or
FLT3-TKD1 BaF3 cells have resistance to a wide range of FLT3
inhibitors (AC220, sorafenib, PLX3397, ponatinib, and DCC2036).7
Additional studies have further validatedmutated FLT3 as an oncogenic
driver and therapeutic target.7 Growth inhibition at CCT241736
concentrations ,100 nM was observed against all FLT3 mutation–
expressing cell lines studied (Table 1). Importantly, although the potent
and selective FLT3 inhibitor AC220 displayed lower absolute GI50
values compared with CCT241736, the relative resistance of BaF3
cells with FLT3-TKD mutations to AC220 was 29- to 237-fold
compared with cells with FLT3-ITD. In contrast, the relative resistance
to CCT241736 was only 1.4- to 1.8-fold. The effect of CCT241736 on
FLT3 phosphorylation was also examined in BaF3 cells engineered to
express mutant FLT3-ITD1 or FLT3-ITD1-F691L. In both cell lines,
CCT241736 produced a dose-dependent decrease in the phosphor-
ylation of FLT3, which indicates robust potency in both mutants
(Figure 2B).
It has been shown that, despite constitutive FLT3 signaling, FLT3-
ITD1 cells are further activated by FL. Endogenous FL expression
promotes leukemic proliferation and reduces survival in FL knockout
mouse models.22 The effect of exposure to 10 ng/mL FL on the
in vitro efficacy of CCT241736 was therefore assessed in MOLM-
13 cells and compared with MLN518 and AC220. Cytarabine was
used as a nonspecific cytotoxic control. MLN518 and AC220 were
most affected by high FL levels, whereas CCT241736 displayed no
resistance to FL, in line with its relative selectivity and potency
against both FLT3 and Aurora kinases (Figure 2C).
In vivo efficacy of CCT241736 in AML xenografts and
in FLT3 inhibitor-resistant models
We tested whether the in vitro findings translated to the in vivo
context. We carried out human tumor xenograft experiments (MOLM-
13) in athymic mice to evaluate the efficacy of CCT241736 in vivo.
CCT241736 reduced tumor growth compared with that in vehicle-
treated mice in a dose-dependent manner with no observed toxicity
on chronic dosing (Figure 3A).
To analyze the PD activity of CCT241736 in vivo, tumors were
collected at 2 hours after the final dose, and the lysates were
analyzed by immunoblotting. Reduction of phospho-Aurora-A and
phospho-STAT5 indicates inhibition of both Aurora A and FLT3 in
a dose-dependent manner (Figure 3B). Similarly, survivin levels
were reduced in a dose-dependent manner, which indicates that
CCT241736 induced apoptosis in vivo. A confirmatory study in
a second in vivo FLT3-ITD1 AML human tumor xenograft model
(MV4-11) showed that CCT241736 significantly inhibits the growth
of MV4-11 xenografts with clear inhibition of both HH3 and STAT5
phosphorylation at 2 hours after the final dose, indicating a dual
inhibition of both Aurora and FLT3 downstream pathways in the
tumor.15 To demonstrate that Aurora kinase inhibition by CCT241736
makes a significant contribution to efficacy in FLT3-mutated AML,
samples of theMV4-11 tumors from the animals dosedwith 100mg/kg
at 2 hours after administration were analyzed by immunofluorescence
microscopy. More than one third (36%) of mitotic cells from tumors
treated with CCT241736 formed monopolar or abnormal spindles,
a typical phenotype for Aurora kinase inhibition.23 In comparison, this
phenotype was observed in only 4% of mitotic cells in tumors from
mice treated with vehicle control (Figure 3C-D). These data confirm the
contribution of Aurora inhibition by CCT241736 to the in vivo efficacy
and the already known induced phenotype from previous studies using
Aurora inhibitors.23
The anti-tumor efficacy of CCT241736 and MLN518 were examined
in an efficacy study using mouse xenografts of the MOLM-13-RES
cell line. MOLM-13-RES cells remained sensitive to CCT241736,
with an in vitro viability IC50 of 0.18 mM, which reflects a 1.8-fold
difference in sensitivity compared with parental MOLM-13 cells. In
contrast, the relative resistance of MOLM-13-RES cells to MLN518
was ;100-fold (Table 1). In addition, cellular assays of MOLM-13-
RES cells with CCT241736 showed a similar pattern of FLT3 and
Aurora inhibition as in MOLM-13 cells (Figures 1C and 2A). To
confirm the in vitro activity of CCT241736 against the MOLM-13-
RESmodel of selective FLT3 inhibitor resistance, in vivo studies were
performed using subcutaneous human tumor xenografts of MOLM-
13-RES cells in athymic mice and the indicated compounds at
their maximum tolerated doses (CCT241736 100 mg/kg twice
per day; MLN518 160 mg/kg twice per day). As illustrated in
Figure 4A, CCT241736 caused a significant in vivo growth inhibition
in comparison with MLN518 (statistically significant difference was
observed between MLN518 and CCT241736 but not between
vehicle control and CCT241736 or MNL518, respectively). As in the
parental MOLM-13 in vivo studies, biomarker modulation was
consistent with inhibition of both FLT3 and Aurora kinases at well-
tolerated doses (Figure 4B). In contrast, MLN518 caused no growth
inhibition of MOLM-13-RES xenografts and no biomarker modulation
or induction of apoptosis. The study had to be terminated when the
control groups and the arm treated with MLN518 had reached the
license volume limits.















 user on 26 M
ay 2020
We also investigated the development of resistance to CCT241736
in vivo (dosing schedule and duration are presented in supplemental
Figure 3A). MOLM-13 cells (13 107) were injected subcutaneously
into female athymic mice. Once tumors were established (4 days),
groups of 6 mice were administered vehicle control or CCT241736
100 mg/kg twice per day. On day 8, control mice were culled
because of tumor size. By day 13, a tumor in 1 mouse had regressed,
and the mouse was taken off the drug for 13 days to allow for
regrowth; 2 other mice were taken off the drug for 2 days to allow for
tumor regrowth. On day 24, the tumor of 1 of these latter mice was
excised and transplanted as solid fragments into 8 mice.
Dosing of these mice commenced on day 35 at 100 mg/kg twice
per day and continued to day 53 (17 days). At this point, tumors
from 2 mice were excised and used as solid explants in 8 additional
mice each. Other tumors were taken for in vitro sensitivity testing at
this point (passage 2). Dosing of 4 mice from each group began




































































































































































































































































Figure 2. Biomarker modulation by Aurora and FLT3 inhibitors in MOLM-13-RES cells. (A) MOLM-13-RES cells were arrested in mitosis by overnight incubation with
50 ng/mL nocodazole and treated with the indicated concentrations of CCT241736, CCT137690, MLN518, or AMG900 for 2.5 hours. Cell lysates were analyzed for STAT5
and HH3 phosphorylation by immunoblotting using specific antibodies. Total STAT5 and total HH3 were used as controls. The bar graphs (bottom panels) show compound
cellular potency after normalization to the control total proteins. (B) BaF3FLT3-ITD and BaF3FLT3-ITD-F691L cells were treated for 2.5 hours with increasing concentrations of
CCT241736 (20 nM to 10 mM) and with 50 nM AC220. Cell lysates were prepared, FLT3 was immunoprecipitated using a specific FLT3 antibody, and its phosphorylation
was analyzed by immunoblotting with phospho-tyrosin–specific antibodies. The bar graph (bottom panel) shows CCT241736 and AC220 cellular potency after normalization to
the control total proteins. (C) Fold change in viability IC50 with 10 ng/mL FL. MOLM-13 cells were treated with increasing concentrations of cytarabine, CCT241736, AC220,
or MLN518 with or without 10 ng/mL FL for 72 hours. The IC50 values for viability were measured using MTS. Experiments were performed in parallel on 3 separate occasions.
Error bars represent the mean change (6 standard error of the mean [SEM]) in viability IC50 with 10 ng/mL FL compared with viability IC50 with no FL treatment. *P , .05 on
paired Student t test analysis.
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(6 days). Tumors were then allowed to grow for 7 days off therapy
(day 80) before 1 tumor was excised and used to provide solid
explants in 8 additional mice. Animals were allowed to recover for
17 days (day 91), at which point dosing began at 150 mg/kg twice
per day. After 5 days, the dose was reduced to 150 mg/kg once
per day because of weight loss in the mice. Animals were finally
culled after 13 days of dosing (day 107). The growth inhibi-
tion IC50’s were estimated for both CCT241736 and MLN518 in
2 lines established from the tumors taken at passage 2 and 2
lines taken at passage 4 and compared with the parental MOLM-
13 cell line. Effectively, no change was observed in the IC50 of
any cell line to either CCT241736 or the MLN518 (supplemental
Figure 3B-C).
By using an in vitro saturation mutagenesis assay, AC220 resistance-
conferring mutations were identified and reported at 4 residues in the
kinase domain of FLT3-ITD.7 Mutation at 1 of these residues (the
gatekeeper residue [F691]) has also been identified in AC220-
relapsed patients. This substitution conferred a high degree of
resistance to AC220 and was also cross-resistant to sorafenib in cell-
based growth and biochemical assays.7 These data suggest that
substitutions at F691 in FLT3-ITD will pose substantial barriers to



























CCT241736 0.09 0.048 0.083 1.7 0.075 1.6 0.068 1.4 0.089 1.8 0.084 1.7
AC220 1.4 0.0003 0.046 155 0.009 31 0.009 29 0.07 237 0.017 56


































































Figure 3. In vivo efficacy of CCT241736 in MOLM-13 human tumor xenografts. (A) Athymic mice (8 per cohort) were injected subcutaneously with 2 3 106 MOLM-13
cells. Five days after implantation, mean tumor diameter was 6 mm (day 0 on graph), and dosing began orally twice per day with vehicle, 25, 50, or 100 mg/kg. Tumor volumes
were measured at days 0, 3, 5, 7, 10, and 12. Mean tumor volumes 6 SEM are shown. Unpaired Student t test of 95% confidence intervals on day 7. ns, not significantly
different (P 5 .14; control: CCT241736 at 25 mg/kg). **P 5 .08 (control: CCT241736 at 50 mg/kg); ****P , .0001 (control: CCT241736 at 100 mg/kg). (B) Biomarker
modulation by CCT241736 in MOLM13 xenograft samples. Tumors were removed 2 hours after the final dose, and lysates were prepared. Equal amount of proteins from all
the tumors were analyzed by immunoblotting using the indicated antibodies for P-STAT5 and Aurora signaling (P-Aurora A, survivin). GAPDH was used as loading control. (C)
CCT241736 induces aberrant mitosis in MV4-11 xenograft tumors. Tumors from mice treated with 100 mg/kg CCT241736 for 18 days (orally twice per day) were removed
2 hours after the final dose and analyzed by immunofluorescence using a-tubulin (green) antibodies and DAPI (blue) (403 magnification). (D) Quantification of mitotic cells. At
least 50 mitotic cells in control and treated tumors were counted for bipolar or aberrant mitosis.
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disease control in AML patients treated with either AC220 or
sorafenib; therefore, they represent high-value targets for efforts to
develop novel FLT3 inhibitors. To examine the sensitivity of FLT3-ITD-
F691L–resistant mutants to CCT241736, we performed in vivo
studies using a model to simulate AML with the clinically relevant
gatekeeper dual FLT3-ITD-F691L–resistant mutant. SCID mice
injected intravenously with FLT3-ITD-F691L luciferase-expressing
BaF3 cells were imaged to detect tumor establishment on day 4 and
were randomly assigned to treatment groups: vehicle control,
CCT241736 at the maximum tolerated dose of 100 mg/kg twice
per day and AC220 at the maximum tolerated dose of 5 mg/kg once
per day. Animals were imaged during treatment and culled
when the systemic disease was evident in livers and spleens.
On day 7 after the treatment, initiation of the total flux (protons/s)
as a surrogate for tumor burden in bioluminescence imaging
(expressed as percent of vehicle control) was as follows: AC220,
105%, and CCT241736, 42%, which confirmed that in this
model there was a significant benefit of CCT241736 treatment
in reducing tumor growth when compared with the FLT3
selective inhibitor AC220 (Figure 4C; supplemental Figure 4).
Statistically significant difference was observed between AC220
and CCT241736.
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Figure 4. In vivo efficacy of CCT241736 in FLT3 inhibitor–resistant xenografts. (A) Athymic nude mice (6 per cohort) were injected subcutaneously with 2 3 106
MOLM-13-RES cells. Thirteen days after implantation, mean tumor diameter was 6 mm (day 0 on graphs), and dosing began orally twice per day for 5 days with solvent
vehicle, CCT241736 at 100 mg/kg twice per day or MLN518 at 160 mg/kg twice per day. Tumor volumes were measured at days 0, 1, 2, and 5. Mean tumor volumes 6 SEM
are shown. Mice were culled at 1 and 6 hours after the final dose. Unpaired Student t test of 95% confidence intervals on day 5. ns, P 5 .13 (control: MLN518) or P 5 .4
(control: CCT241736). Significantly different, *P 5 .02 (MLN518:CCT241736). (B) Tumor lysates were analyzed by immunoblotting for expression of the indicated proteins.
GAPDH, Aurora A, and STAT5 were used as controls. The bar graphs (bottom panel) show the in vivo potency of compounds after normalization to the control total proteins.
(C) Systemic model of BaF3FLT3-ITD F691L luciferase–expressing tumors in NOD SCID mice. On day 7, the flux in the treated groups (mean total flux 6 SEM) is indicated.
Mice were dosed (starting 4 days after tumor cell implantation and randomization) with AC220 at 5 mg/kg orally once per day or CCT241736 at 100 mg/kg orally twice
per day, and tumor burden was assessed by whole-body bioluminescent imaging. Animals were culled when they showed signs of deterioration as a result of tumor burden
(body weight loss, rapid breathing). Unpaired Student t test of 95% confidence intervals on day 7. ns, P 5 .6 (control: AC220) or P 5 .1 (control: CCT241736). Significantly
different, *P 5 .01 (AC220:CCT241736).
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CCT241736 potency in primary AML cells
To investigate whether CCT241736 has activity in primary AML cells,
we obtained peripheral blood blasts from quizartinib-responded (13
samples: AML-1 to AML-13; supplemental Table 1) and quizartinib-
relapsed (3 samples: AML-7, AML-14, and AML-15; Table 2 in bold)
patients with diverse molecular characteristics, including those with
FLT3 WT, FLT3-ITD, IDH1/2, and NPM1 mutations.24,25 AML cells
from quizartinib-responded patients (AML-1 to AML-13) were
cocultured in triplicate onto irradiated MS-5 fibroblasts and treated
with 3 different concentrations of CCT241736 (0.3, 1, and 3 mM).
Three days after treatment, cells were harvested and counted using
a Luna-II Automated Cell Counter (Labtech). Annexin V and Vybrant
FAM caspase-3/-7 assays were also used to assess apoptosis.
In pooled samples, CCT241736 showed induction of apoptosis
as measured by annexin V and caspase-3/-7 assays (Figure 5A;
supplemental Figure 5A-M) and a consistent reduction of cell viability
independently of FLT3, IDH1/2, or NPM1 status (Figure 5B). Detailed
analysis showed that in 6 samples (AML-2, AML-3, AML-6, AML-7,
AML-12, AML-13), CCT241736 induced apoptosis as measured
by annexin V and caspase-3/-7 assays and consistently reduced
cell viability independently of FLT3, IDH1/2, or NPM1 status. Six
additional samples (AML-1, AML-4, AML-8, AML-9, AML-10,
AML-11) responded to CCT241736 at higher concentrations
(3 mM), whereas only 1 sample (AML-5 with FLT3 WT and
NPM1) did not respond (supplemental Figure 5A-M). To investigate
the cause of cell death, we determined the effect of CCT241736
(1 mM for 4 hours) on P-STAT5 and Aurora pathways in 2 samples of
CCT241736-responsive primary AML samples (1 FLT3WT [AML-2]
and 1 FLT3-ITD [AML-6]; Figure 5C-E). Phospho-STAT5, the
downstream marker for FLT3 inhibition, was reduced in both samples
(Figure 5C). HH3 phosphorylation, indicative of Aurora inhibition, was
reduced by;25% to 35% in both samples (Figure 5D). Immunoblots
are presented in Figure 5E. These data confirm that the potency of
CCT241736 in primary AML samples and in in vivo experiments is
a result of the inhibition of both FLT3 and Aurora.
We expanded this investigation by using samples from 3 quizartinib-
relapsed patients (AML-7, AML-14, and AML-15; Table 2 [bold]).
Further characterization of these samples identified FLT3-TKD
mutations in a sample from AML-14 (D835Y and D835del) and
in a sample from AML-15 (D835del and M837del). Additional
mutations of RUNX1 gene were found in AML-15 (D93fs and
L110Q; Table 2).26 None of the above gene alterations were
identified in quizartinib-resistant sample from AML-7. We tested
cell viability and apoptosis induction of quizartinib and
CCT241736 in these samples. Quizartinib showed no effect
on any of these parameters, whereas CCT241736 clearly
showed a reduction of viable cells (Figure 6) and induction of
apoptosis as measured by the induction of caspase-3/-7 activity
and annexin V staining (supplemental Figure 6). These results
suggest that dual inhibition of FLT3 and Aurora kinases by
CCT241736 sensitizes AML cells with various quizartinib-
resistant mutations to death.
Discussion
Several small molecule kinase inhibitors with FLT3 activity have
been evaluated in relapsed or refractory AML patients in clinical
trials. These include lestaurtinib (CEP 701), midostaurin (PKC-
412), sorafenib (BAY-43-9006), sunitinib, (SU-11248), and tandu-
tinib (MLN518).27-31 Second-generation inhibitors have now been
developed that show greater selectivity and low nanomolar target
inhibition; such agents include KW-2449 and quizartinib (AC220).32,33
Although these inhibitors (as monotherapies) have demonstrated
moderate efficacy, the emergence of resistance and relapse has been
challenging.
Several resistance mechanisms have been identified. Primary
resistance involves reduced potency as well as adverse effects on
bone marrow leukemia cells and circulating blasts; for example,
quizartinib induces apoptosis in the circulating blasts but promotes
differentiation of bone marrow blasts.4,34 Secondary resistance also
involves regaining sensitivity to FL whose expression is reported to
increase immediately after chemotherapy.4,9 In addition, it has been
reported that patients who relapse after FLT3 therapy develop point
mutations around the adenosine triphosphate–binding pocket or
a gatekeeper mutation (D835Y, D835V, D835F, or F691L), thus
blocking inhibitor binding.7,35,36 Several FLT3 inhibitors are now
being clinically investigated in combination with other agents in an
attempt to prevent the occurrence of resistance.37,38
As critical mitotic kinases, Aurora A and Aurora B have been
targeted with numerous small molecules. For FLT3-ITD1 AML,
several Aurora kinase inhibitors have demonstrated efficacy
in early-phase clinical trials.11 In this study, we aimed to
characterize CCT241736 as a dual FLT3-Aurora inhibitor both
in vitro and in vivo, to determine its mechanism of action, and to
evaluate its ability to overcome resistance to selective FLT3
inhibitors.
CCT241736 is a potent dual inhibitor of FLT3 and Aurora kinases
with few off-target kinase activities across the kinome, namely JAK2
and Axl.15 JAK2 signaling has been associated with the mainte-
nance of AML stem cells and thus may represent a target in AML.
The JAK2 inhibitory activity of CCT241736 may act to prevent the
occurrence of resistance.39 Phosphorylation of Axl has been shown
to be upregulated after exposure to the FLT3 inhibitor AC220 in
both an FLT3-ITD1 AML cell line (MV4-11) and in primary blasts.
The Axl inhibitory activity of CCT241736 thus may also act to prevent
the occurrence of resistance.40 The PK profile of CCT241736 in
Table 2. Characteristics of primary AML samples from quizartinib-








AML-7 Normal Intermediate Mutant ITD Not tested
AML-7 Normal Intermediate Mutant ITD WT
AML-14 t(6;9)(p23;
q34.1)








AML-15 113 Intermediate WT ITD Not tested
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mice and rats revealed a highly orally bioavailable compound with low
clearance and a moderate volume of distribution.15
In cellular assays, CCT241736 potently inhibited the proliferation
of cell lines with both mutated and WT FLT3. This inhibition was
associated with the induction of apoptosis as measured by PARP
cleavage as well as downregulation of survivin. The cell cycle
profile of CCT241736, with temporary G1-S and G2-M arrest, is
differentiated from selective FLT3 inhibition and pan-Aurora
inhibition and phenocopies cells treated simultaneously with
an FLT3 inhibitor (MLN518) and a pan-Aurora inhibitor (PHA-
739358). These results together provide an explanatory model for
understanding the unique mechanism of action of CCT241736
targeting of AML (Figure 6D).
On the basis of its in vitro pharmacologic profile, we carried out
human tumor xenograft experiments in athymic mice to evaluate the
efficacy of CCT241736 in vivo. CCT241736 demonstrated dose-
dependent reduction of tumor growth in a MOLM-13 subcutaneous
human tumor xenograft model with PD modulation of biomarkers,
which indicated both FLT3 and Aurora kinase inhibition. Importantly,
we have also shown (by immunofluorescence microscopy of tumor
sections) that CCT241736 induces abnormal mitosis in MV4-11
tumor cells, a characteristic phenotype of Aurora inhibition. These
data suggest that the CCT241736-induced Aurora inhibitory
effects also contribute to the observed in vivo efficacy in these
models.
To test the hypothesis that dual FLT3-Aurora inhibition could
overcome resistance to selective FLT3 inhibition, we have used
MOLM-13-RES cells (pD835Y), generated in our laboratory
in the presence of increasing concentrations of the selective
FLT3 inhibitor MLN518.17 Additional studies showed that
CCT241736 retained efficacy against MOLM-13-RES cells
grown as subcutaneous xenografts with biomarker modulation
compared with MLN518. Long-term treatment of AML xenografts
with CCT241736 (over 4 months) failed to show evidence of
loss of responsiveness, which builds confidence that the dual
pharmacologic profile of this compound (Aurora and FLT3
inhibition) abrogates or significantly delays the development of
resistance.
The potency of CCT241736 was also confirmed in other clinically
relevant secondary FLT3-TKD mutations in vitro in a panel of mouse
BaF3 AML cells that expressed different FLT3 mutants.7 Impor-
tantly, we have investigated the in vivo efficacy of CCT241736 in
a systemic model by using cells that express FLT3 with a mutated
gatekeeper residue (F691) that has been identified in AC220-
treated patients who have relapsed. It was shown that CCT241736
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Figure 5. The effect of CCT241736 on cell viability
and induction of apoptosis and biomarker modula-
tion of primary AML cells. (A-B) Primary cells from AML
samples with FLT3 WT and FLT3-ITD were cocultured
with MS-5 and treated with either DMSO control or
CCT241736 at indicated doses. (A) Three days after
treatment, cells were harvested, washed, and stained with
annexin-V/DAPI. (B) Viable cells were counted using
a Luna-II Automated Cell Counter. (C-E) Primary AML
samples AML-2 (FLT3 WT) and AML-6 (FLT3-ITD) were
treated with 1 mM CCT241736 and DMSO for 4 hours,
the relative levels of P-STAT5 vs total STAT5 (C), and
P-HH3 vs total HH3 (D) were analyzed by immunoblotting
using specific antibodies (E). All experiments were performed
in triplicate, and results were shown as mean 6 SEM.
*P , .01 compared with control.
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CCT241736 treatment in reducing tumor growth in this model
when compared with AC220.
Patient samples with FLT3 WT, FLT3-ITD, and WT or mutated
NPM1 and IDH1/2 genes were sensitive to CCT241736 with
biomarker modulation, demonstrating that CCT241736 is a potent
inhibitor of FLT3 and Aurora kinases in primary patient cells.
More importantly, sensitization to death of primary cell samples
from quizartinib-relapsed AML patients by CCT241736 offers
the opportunity to progress a new therapeutic strategy in this
particularly aggressive subtype of AML. Overall, the unique kinase
inhibitory profile of CCT241736, with inhibitory activity toward both
FLT3 and Aurora kinases, may yield an agent that has persistent
clinical activity against AML with a low incidence of acquired
resistance.
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Figure 6. The effect of AC220 and CCT241736 on cell viability of quizartinib-resistant primary AML cells. (A-C) Primary AML cells were collected from 3 patients
with quizartinib-resistant AML (AML-7, AML-14, and AML-15). The AML cells were collected after clinical quizartinib resistance had emerged at the point of relapse. Cells were
cocultured in triplicate with irradiated MS-5 at a density of 1.2 million cells per milliliter and were treated with either DMSO control, AC220 (left graphs), or CCT241736 (right
graphs) at the indicated doses. Three days after treatment, cells were harvested, and viable cells were counted using a Luna-II Automated Cell Counter. All experiments were
done in triplicate and results were shown as mean 6 SEM (*P , .05 compared with control). (D) Explanatory model: activated FLT3 induces the transcription of several
downstream genes, including the Aurora B partner survivin, via STAT1, -3, and -5 proteins. Aurora A plays a role in centrosome maturation and spindle formation, whereas
Aurora B regulates the spindle checkpoint in kinetochore microtubule attachment and cytokinesis. CCT241736 inhibits Aurora kinases and the FLT3 pathway in multiple steps.
This inhibition leads to cytokinesis failure and inhibition of leukemic proliferation.
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